MetaVia Inc. filed a current report on Form 8-K on November 16, 2026, disclosing positive preclinical data from a head-to-head study comparing its dual OXM analog DA-1726 against retatrutide in diet-induced obese mice, presented on November 14, 2026.

Key Highlights

  • Study design: Diet-induced obese mice received twice-weekly subcutaneous injections of DA-1726 at 300 or 500 nmol/kg or retatrutide at 100 or 200 nmol/kg for approximately three weeks.
  • Body weight reductions: DA-1726 achieved reductions of 34.2% and 41.7% at low and high doses, compared with 33.7% and 43.6% for retatrutide, after adjustment relative to the diet-induced obese control group.
  • Glucose lowering: Plasma glucose decreased by 43.0% and 39.2% with DA-1726 at low and high doses, versus 21.5% and 32.5% for retatrutide.
  • Cholesterol reduction: DA-1726 reduced total cholesterol by 70.9% and 69.3%, compared with 60.9% and 69.0% for retatrutide; LDL cholesterol fell by 89.9% and 88.4%, compared with 82.8% and 88.1% for retatrutide.
  • Food intake suppression: DA-1726 reduced food intake by 19.6% and 31.2%, compared with 36.7% and 41.4% for retatrutide, according to the filing.
  • Thermogenesis markers: DA-1726 induced greater expression of genes associated with brown adipose tissue thermogenesis and white adipose tissue browning, including Ucp1, Ppargc1a, and Fgf21, with several markers showing significantly greater expression than high-dose retatrutide.

DA-1726 Preclinical Findings: Weight Loss, Glucose, and Metabolic Effects

According to the filing, MetaVia Inc. (NASDAQ:MTVA) presented preclinical data on November 14, 2026, from a study evaluating DA-1726, described as "a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors," against retatrutide, described as "a triple GLP1R/GIPR/GCGR agonist." The higher doses used in the study were selected based on pharmacokinetic exposure estimates intended to approximate clinical exposures of 48 mg for DA-1726 and 12 mg for retatrutide, the filing states.

The filing reports that DA-1726 achieved body weight reductions comparable to retatrutide despite less suppression of food intake. MetaVia disclosed that DA-1726 demonstrated increased hepatic expression of fibroblast growth factor 21 (Fgf21), increased liver FGF21 protein, and a numerical increase in circulating FGF21 at the higher dose. The filing states that "these findings suggest that glucagon receptor-associated metabolic pathways, including those involving FGF21 and thermogenesis, may contribute to DA-1726's weight-loss effects." Both treatments also demonstrated comparable effects on body composition, including substantial reductions in fat mass, according to the filing.

On lipid parameters, the filing reports that both compounds showed improvements, with DA-1726 and retatrutide producing broadly comparable total cholesterol and LDL cholesterol reductions at the higher doses. The filing notes that "these findings suggest a potentially greater contribution of glucagon receptor-associated energy expenditure to weight loss with DA-1726 than with retatrutide." The report contains forward-looking statements that, according to the filing, "are based on current expectations and are not guarantees of future performance," and actual results may differ materially from those described.

What Was Disclosed

MetaVia Inc. disclosed preclinical head-to-head comparison data for DA-1726 versus retatrutide in diet-induced obese mice, covering body weight, food intake, glucose, lipid parameters, and thermogenesis-related gene expression, via a current report and accompanying press release dated November 16, 2026.